Conversely, those treated with high-dose interleukin-2 (IL-2) for melanoma and renal cell carcinoma show expansion of these cells (Ahmadzadeh and Rosenberg, 2006). Here, IL2 is linked to hereditary clear cell renal cell carcinoma.